Hence, we suggest that genes included in these pathways may be used as markers for CML development (FOS, TGFBR2, TPX2) and CML resistance to therapy (LAPTM4B, HLTF, PIEZO2, CFH, CD109, ANGPT1). This evidence concerns the gene ANGPT1 and chronic myelogenous leukemia, BCR-ABL1 positive.